Nebulized enriched heparin to treat no critical patients with Sars-Cov-2: Triple-blind clinical trial.
Matheus BertanhaLenize da Silva RodriguesPedro Luciano MellucciAndrei MorozMaria Inês de Moura Campos PardiniMarcone Lima SobreiraEdison Luiz DurigonRafael Rahal Guaragna MachadoRejane Maria Tommasini GrottoMarcelo Andrade de LimaHelena Bonciani NaderMarli Leite de MoraesAlexandre Naime BarbosaNatália Bronzatto MedolagoFábio Florença CardosoAngelo José MagroCristiane Rodrigues Guzzo CarvalhoLeonardo Nazario de MoraesRita de Cássia AlvaradoHelga Caputo NunesGustavo Constantino de CamposVinicius Tadeu Ramos da Silva GrilloNathalia Dias SertorioCarlos Magno Castelo Branco FortalezaPublished in: Medicine (2022)
A phase I/II triple-blind parallel clinical trial will be conducted. Fifty participants with radiological diagnosis of grade IIA pneumonia will be selected, which will be allocated in 2 arms. Participants allocated in Group 1 (placebo) will receive nebulized 0.9% saline. Participants allocated in Group 2 (intervention) will receive nebulized enriched heparin (2.5 mg/mL 0.9% saline). Both groups will receive the respective solutions on a 4/4 hour basis, for 7 days. The main outcomes of interest will be safety (absence of serious adverse events) and efficacy (measured by the viral load).Protocols will be filled on a daily basis, ranging from day 0 (diagnosis) until day 8.